Our Story
From vision to reality
Metanoia was born from a simple observation: while psychedelic research has made remarkable strides in treating mental health conditions, there remains a vast, unexplored frontier—understanding how these compounds can benefit healthy individuals seeking personal growth, enhanced creativity, and deeper self-awareness.
Founded in 2025, Metanoia brings together researchers, practitioners, and advocates united by a shared vision: to bridge the gap between clinical applications and the broader potential of psychedelics for human flourishing. Our name comes from the Greek word meaning "a transformative change of heart" or "a fundamental shift in thinking"—perfectly capturing our mission to expand understanding of consciousness and personal development.
Our unique hybrid structure—combining a U.S. 501(c)(3) nonprofit with an Israel-based research affiliate—allows us to pursue our mission with both the rigorous scientific standards expected of academic research and the innovative approaches necessary to push the boundaries of current understanding.
Today, Metanoia stands at the forefront of a new wave of psychedelic research, one focused not on treating pathology, but on unlocking human potential. We believe that by understanding the mechanisms through which psychedelics enhance creativity, foster emotional resilience, and deepen self-knowledge, we can contribute to a more conscious, connected, and flourishing humanity.
